A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the safety, tolerability and pharmacokinetic profile of EMA401 (angiotensin II type 2 receptor antagonist) administered orally in patients with postherpetic neuralgia.

Trial Profile

A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the safety, tolerability and pharmacokinetic profile of EMA401 (angiotensin II type 2 receptor antagonist) administered orally in patients with postherpetic neuralgia.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs EMA 401 (Primary)
  • Indications Postherpetic neuralgia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Spinifex Pharmaceuticals
  • Most Recent Events

    • 30 Sep 2016 Results of sub-group anaysis (subgroup of patients taking or not taking any concomitant medications) presented at the 16th World Congress on Pain
    • 08 Feb 2014 Results published in the Lancet.
    • 05 Feb 2014 Results have been published in the Lancet according to a Spinifex Pharmaceuticals media release. Results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top